Zai Lab

(NASDAQ) ZLAB

Current Price$20.75

Market Cap$2.31B

Since IPO (2017)+14%

5 Year-87%

1 Year-42%

1 Month+17%

Zai Lab last closing stock price
Metric	Price	Date
Last close	USD 20.75	2026-07-16

Zai Lab stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+3.85%	USD 19.98	2026-07-09
1 month	+17.03%	USD 17.73	2026-06-16
3 month	-14.22%	USD 24.19	2026-04-17
Year to date	+17.63%	USD 17.64	2025-12-31
1 year	-41.5%	USD 35.47	2025-07-16
3 year	-24.93%	USD 27.64	2023-07-17
5 year	-86.76%	USD 156.72	2021-07-16
Since inception	+13.56%	USD 18.00	2017-09-18

Zai Lab Financials at a Glance

Market Cap

$2.31B

Revenue (TTM)

$453.28M

Net Income (TTM)

-$178.12M

EPS (TTM)

-$1.62

P/E Ratio

-12.61

Dividend

$0.00

Beta (Volatility)

1.20 (Average)

Dividend

$0.00

Beta (Volatility)

1.20 (Average)

Price

$20.75

Volume

654,372.879

Open

$20.49

Price

$20.75

Volume

654,372.879

Open

$20.49

Previous Close

$20.75

Daily Range

$20.43 - $20.89

52-Week Range

$15.96 - $41.20

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.20 (Average)

Price

$20.75

Volume

654,372.879

Open

$20.49

Previous Close

$20.75

Daily Range

$20.43 - $20.89

52-Week Range

$15.96 - $41.20

Estimated Earnings Date

Aug 6, 2026

ZLAB News

Buy These 2 Stocks to Access China's Huge Healthcare Market

David HaenNov 6, 2019

3 Top Chinese Stocks to Watch in May

Jeremy BowmanMay 1, 2019

George Soros Bought These 2 Healthcare Stocks in the Third Quarter

George Budwell, PhDDec 3, 2018

Page 1

ZLAB: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zai Lab

Zai Lab makes medicines for cancer and serious infections. These help patients find new ways to treat complex diseases. The company serves people in China and the United States.

Specialized Tools for Patient Health

Oncology Programs: Cancer therapies like Zejula and Optune help patients manage tumors and various cancers.
Immunology Products: Rare disease treatments like Vyvgart address autoimmune conditions that weaken the muscles.
Infectious Disease Drugs: Bacterial infection medicines such as Nuzyra and Xacduro treat serious illness in hospital settings.

Growing Through New Partnerships

Joined a clinical collaboration with Amgen in April 2026 to test combined lung cancer treatments.
Started a partnership with Boehringer Ingelheim in April 2026 to study a new oncology drug.
Licensed a new antibody from Zenas BioPharma in January 2025 for development in Greater China.
Recorded a milestone fee for a collaboration with MediLink Therapeutics in the first quarter of 2026.

A Bridge Between Global Markets

Zai Lab operates research and commercial teams in both China and the United States. This structure helps the business bring international medical innovations to the Chinese market quickly.

Tracking the Latest Financial Results

Total revenue reached $99.6 million in Q1 2026, down 6.5% from Q1 2025.
Net loss deepened to $51.0 million in Q1 2026, worsening 5.3% from Q1 2025.
Free cash flow improved to negative $34.2 million in Q1 2026, up 47.8% from Q1 2025.
Operating cash flow hit negative $11.9 million in Q1 2026, an 80.7% improvement year-over-year.

Evolution of the Business

Zai Lab has transitioned from a research startup to a company with seven commercial products on the market. Its strategy relies on building a broad pipeline through international partnerships and internal discovery.

AI Generated • May 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,784

CEO

Ying Du, PhD

Website

www.zailaboratory.com

Headquarters

Shanghai, SH 201210, CN

ZLAB Financials

Key Financial Metrics (TTM)

Gross Margin

57.91%

Operating Margin

-53.49%

Net Income Margin

-39.29%

Return on Equity

-24.29%

Return on Capital

-23.79%

Return on Assets

-16.23%

Earnings Yield

-7.93%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.31B

Shares Outstanding

112.92M

Volume

654.37K

Avg. Volume

909.25K

Financials (TTM)

Gross Profit

$262.51M

Operating Income

-$242.40M

EBITDA

-$158.45M

Operating Cash Flow

-$101.00M

Capital Expenditure

-$28.23M

Free Cash Flow

-$129.23M

Cash & ST Invst.

$661.32M

Total Debt

$231.91M

Zai Lab Performance Analysis

Zai Lab annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 214,784,487	48.6%
2023	2023-12-31	USD 266,487,150	24.1%
2024	2024-12-31	USD 399,188,124	49.8%
2025	2025-12-31	USD 461,372,991	15.6%

Zai Lab sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	3.3%
Q3	2025-09-30	5.6%
Q4	2025-12-31	9.9%
Q1	2026-03-31	-21.9%

Zai Lab annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -4.62	-39.1%
2023	2023-12-31	USD -3.46	-25.1%
2024	2024-12-31	USD -2.60	-24.9%
2025	2025-12-31	USD -1.61	-38.2%

Zai Lab sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	16.5%
Q3	2025-09-30	11.8%
Q4	2025-12-31	-39.4%
Q1	2026-03-31	-8.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$99.61M

-6.5%

Gross Profit

$61.28M

-9.7%

Gross Margin

61.52%

N/A

Market Cap

$2.31B

N/A

Market Cap/Employee

$1.29M

N/A

Employees

1,784

N/A

Net Income

-$51.02M

-5.3%

EBITDA

-$44.00M

-0.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$661.32M

-12.7%

Total Debt

$231.91M

+20.6%

Accounts Receivable

$54.07M

-38.3%

Inventory

$85.96M

+62.0%

Long Term Debt

$12.11M

-1.7%

Short Term Debt

$219.80M

+22.1%

Return on Assets

-16.23%

N/A

Return on Invested Capital

-34.46%

N/A

Free Cash Flow

-$34.20M

+47.8%

Operating Cash Flow

-$11.91M

+80.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TARSTarsus Pharmaceuticals, Inc.

TARSTarsus Pharmaceuticals, Inc.$57.69+0.33%

AAPGAscentage Pharma Group International

AAPGAscentage Pharma Group International$20.40+1.09%

IRONDisc Medicine, Inc.

IRONDisc Medicine, Inc.$73.47-3.35%

IDYAIDEAYA Biosciences, Inc.

IDYAIDEAYA Biosciences, Inc.$35.93-2.20%

LEGNLegend Biotech Corporation

LEGNLegend Biotech Corporation$22.71-1.43%

XENEXenon Pharmaceuticals Inc.

XENEXenon Pharmaceuticals Inc.$66.98-1.08%

CDTXCidara Therapeutics, Inc.

CDTXCidara Therapeutics, Inc.$221.38+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$15.60-0.00%

ATAIAtaiBeckley

ATAIAtaiBeckley$7.15+0.33%

NOKNokia

NOKNokia$10.38-0.08%

ONDSOndas

ONDSOndas$6.65-0.06%

PATHUiPath

PATHUiPath$12.03+0.01%

TAT&T

TAT&T$21.98+0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$70.74-0.05%

Questions About ZLAB

What is the current price of Zai Lab?

Zai Lab is trading at $20.75 per share.

What is the 52-week range for Zai Lab?

Over the past 52 weeks, Zai Lab has traded between $15.96 and $41.20.

How much debt does Zai Lab have?

As of the most recent reporting period, Zai Lab reported total debt of $231.92M.

How much cash does Zai Lab have on hand?

Zai Lab reported $751.34M in cash and cash equivalents in its most recent financial results.

What is Zai Lab’s dividend yield?

Zai Lab does not currently have a dividend yield.

Zai Lab

Zai Lab Financials at a Glance

ZLAB News

Why Shares of Zai Lab Limited Were Jumping on Tuesday

Why Shares of Zai Lab Are Dropping Wednesday

1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off

2 Stocks That Could Rebound and Rise 30% or More in 2023

Why Shares of Zai Lab Soared This Week

Buy These 2 Stocks to Access China's Huge Healthcare Market

3 Top Chinese Stocks to Watch in May

George Soros Bought These 2 Healthcare Stocks in the Third Quarter

ZLAB: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Zai Lab

Specialized Tools for Patient Health

Growing Through New Partnerships

A Bridge Between Global Markets

Tracking the Latest Financial Results

Evolution of the Business

ZLAB Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Zai Lab Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ZLAB

What is the current price of Zai Lab?

What is the 52-week range for Zai Lab?

How much debt does Zai Lab have?

How much cash does Zai Lab have on hand?

What is Zai Lab’s dividend yield?

Premium Investing Services